Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response.
Kuperberg M, Köhler-Forsberg O, Shannon AP, George N, Greenebaum S, Bowden CL, Calabrese JR, Thase M, Shelton RC, McInnis M, Deckersbach T, Tohen M, Kocsis JH, Ketter TA, Friedman ES, Iosifescu DV, Ostacher MJ, Sylvia LG, McElroy SL, Nierenberg AA.
Kuperberg M, et al. Among authors: ketter ta.
J Affect Disord. 2022 Mar 1;300:41-49. doi: 10.1016/j.jad.2021.12.047. Epub 2021 Dec 21.
J Affect Disord. 2022.
PMID: 34952123
Clinical Trial.